CSCamille Sibertin-Blanc

Camille Sibertin-Blanc

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Camille Sibertin-Blanc has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.

    by Camille Sibertin-Blanc, Aurelie Fabre, Thomas Aparicio, Karine Le Malicot, Jaafar Bennouna, Francois Ghiringhelli, Julien Taïeb, Valerie Boige, Olivier Bouche, Roger Faroux, et al.

    3534 Background: Bevacizumab (Bev) is widely used in mCRC but there is no validated predictive factor. Several studies have reported the impact of SNPs in the Vascular Endothelial Growth Factor-A (VEGF-A) pathway genes on the Bev’s efficacy but results in the mCRC are yet inconstant. PRODIGE 9 is a phase III trial that compare the tumor control duration (TCD) under a 1st-line chemotherapy followed by either Bev maintenance (Arm A) or no treatment during chemotherapy-free intervals (CFI) (Arm B).The aim of our study was to evaluate the impact of genetic polymorphisms of VEGF A, VEGFR1, VEGFR2 and HIF1α on TCD, duration of 1stCFI, progression-free survival (PFS) and overall survival (OS). Methods: We included patients (pts) of the PRODIGE 9 study for whom biological consent was signed and a DNA sample was available. Ten polymorphisms were genotyped on germ line DNA using real-time Polymerase Chain Reaction. DNA was extracted from blood samples. Survival analyses were done using Kaplan-Meier method and Cox model. For tRR, a logistic regression was used. Results: Among the 491 pts randomized in PRODIGE 9, DNA was available for 314 pts: 160 in Arm A and 154 in Arm B . The median TCD, OS and PFS, were respectively 15.7, 22.6 and 9.2 months (m). For VEGFR-1 rs9582036, pts with CC genotype had significantly better TCD (median [95%CI] 22.4 m [14.7- NR]) compared to pts with AA and CA genotypes (14.4 m [11.7-17.1] (p = 0.04)) in arm A whereas there was no difference in the other arm. This tendency was observed also for the 1st CFI (median 4.6 m for pts CC vs 4.1 m for AC and AA), for the median OS (28.2 vs 22.5 m), the RR, but it was not statistically significant (table). Conclusions: In this prospective study, VEGFR-1 rs9582036 variants were associated with clinical outcome in terms of TCD for patients with mCRC treated by Bev-based therapy. Clinical trial information: NCT00952029.


  • Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer

    by Camille Sibertin-Blanc, Julien Mancini, Aurélie Fabre, Arnaud Lagarde, Jean Del Grande, Nicolas Levy, Jean-François Seitz, Sylviane Olschwang, Laetitia Dahan